98991-32-3

CHBO4 is a potent, reversible, competitive, and selective hMAO-B inhibitor with an IC50 value of 0.031 μM in CHBO subseries and an Ki value of 0.010 ± 0.005 μM. CHBO4 reduce cell damage by scavenging intracellular reactive oxygen species (ROS). CHBO4 can be used for Parkinson's Disease (PD) research[1].

hMAO-B: 0.031 μM (IC₅₀); hMAO-B: 0.010 μM (Ki)

[1] Thomas Parambi DG, et al. Halogenated class of oximes as a new class of monoamine oxidase-B inhibitors for the treatment of Parkinson's disease: Synthesis, biochemistry, and molecular dynamics study. Comput Biol Chem. 2023 Aug;105:107899. DOI:10.1016/j.compbiolchem.2023.107899